23 filings
8-K
DMTX
Dimension Therapeutics Inc
7 Nov 17
Ultragenyx Completes Tender Offer and Acquisition of Dimension Therapeutics
12:00am
8-K
DMTX
Dimension Therapeutics Inc
3 Oct 17
Ultragenyx to Acquire Dimension Therapeutics
12:00am
8-K
DMTX
Dimension Therapeutics Inc
2 Oct 17
Other Events
12:00am
8-K
DMTX
Dimension Therapeutics Inc
19 Sep 17
Dimension to Begin Discussions with Ultragenyx
12:00am
8-K
DMTX
Dimension Therapeutics Inc
18 Sep 17
Other Events
12:00am
8-K
xisimawyhb3eund
25 Aug 17
REGENXBIO to Acquire Dimension Therapeutics
12:00am
8-K
lkx5 galkf7chkj5
8 Aug 17
Dimension Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
12:00am
8-K
782n4
24 Jul 17
Departure of Directors or Certain Officers
12:00am
8-K
6fyi3vpmtjozahzpqrt4
27 Jun 17
Dimension Therapeutics Completes Strategic Review and Updates Corporate Priorities
12:00am
8-K
bueq6yjhcif5
26 May 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
ylt e76ggy878ufutz
10 May 17
Dimension Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
12:00am
8-K
dqjj1
3 May 17
Entry into a Material Definitive Agreement
12:00am
8-K
2ixjiiv
9 Mar 17
In December, initiated Phase 1/2 clinical trial of DTX301, Dimension’s lead IMD product candidate for OTC Deficiency; Initial data expected 2H 2017
12:00am
8-K
6s5h0 op4gh
31 Jan 17
Regulation FD Disclosure
12:00am
8-K
4e4 e8s0d
20 Jan 17
Departure of Directors or Certain Officers
12:00am
8-K
ysyxkec6c8tqtmt
10 Nov 16
Dimension Therapeutics Reports Recent Corporate Progress and Third Quarter 2016 Financial Results
12:00am
8-K
bad5emf
11 Aug 16
Regulation FD Disclosure
12:00am
8-K
otbbm7wi3m35et hw
11 Aug 16
Dimension Therapeutics Reports Recent Corporate Progress and Second Quarter 2016
12:00am
8-K
ci0ft7ho0u
20 May 16
Submission of Matters to a Vote of Security Holders
12:00am
8-K
7pbxl0i
12 May 16
Dimension Therapeutics Reports Recent Corporate Progress and First Quarter 2016 Financial Results
12:00am